ALZN实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders...

Stats
今日成交量	18 841.00
平均成交量	56 585.00
市值	4.99M
EPS	$0 ( 2024-03-21 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.400
ATR14	$0.00800 (1.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Ault Milton C Iii	Buy	1 000	Common Stock
2024-04-01	Ault Milton C Iii	Buy	334	Common Stock
2024-01-05	Ault Milton C Iii	Buy	2 000	Common Stock
2024-03-26	Ault Milton C Iii	Buy	780 000	Warrants
2024-03-26	Ault Milton C Iii	Buy	780	Series B Convertible Preferred Stock

INSIDER POWER
-9.66
Last 96 transactions
Buy: 11 786 230 \| Sell: 5 921 131

Alzamend Neuro, Inc. 相关性

10 最正相关
SEDG	0.983
IMUX	0.974
CFRX	0.973
RIDE	0.973
BXRX	0.971
ELEV	0.97
BNGO	0.969
IRDM	0.968
FNCH	0.967
RELI	0.967

10 最负相关
ADAL	-0.973
SLMBP	-0.973
HCNE	-0.971
VMGA	-0.97
JUGG	-0.967
IXAQ	-0.966
HORI	-0.966
GPAC	-0.966
LCAA	-0.964
IBEX	-0.962

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Alzamend Neuro, Inc. 相关性 - 货币/商品

0.08
( neutral )

0.14
( neutral )

0.00
( neutral )

0.22
( neutral )

Alzamend Neuro, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-23 066.00 (0.00 %)
EPS:	$-2.29

FY	2023
营收:	$0
毛利润:	$-23 066.00 (0.00 %)
EPS:	$-2.29

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-2.09

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0594

Financial Reports:

No articles found.

Alzamend Neuro, Inc.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.